Advertisement

Drug Safety

, Volume 33, Issue 7, pp 535–538 | Cite as

Recurrence of Adverse Drug Reactions following Inappropriate Re-Prescription

Better Documentation, Availability of Information and Monitoring are Needed
  • Carolien M. J. van der Linden
  • Paul A. F. Jansen
  • Rob J. van Marum
  • René J. E. Grouls
  • Erik H. M. Korsten
  • Antoine C. G. Egberts
Current Opinion

Abstract

Adverse drug reactions (ADRs) are a common, and often preventable, cause of hospital admission, especially in the elderly, and can occur during hospitalization.

In this current opinion article, we present three cases of recurrence of a serious ADR due to re-prescription of a withdrawn medication that highlight the need for a system to prevent the undesirable re-prescription of medications withdrawn because of an ADR. In addition, we describe an electronic system that could help prevent undesirable re-prescription following an ADR. Such a system should document ADRs systematically at the patient level, make this information available to relevant healthcare providers and the patient, and flag re-prescription of the offending drug. The effectiveness and cost effectiveness of such a system would need to be determined.

Keywords

Haloperidol Hydrochlorothiazide Pamidronate Selegiline Pergolide 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

Carolien van der Linden was financially supported by Catharina Hospitals Science Fund, which had no role in any of the following: design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review or approval of the manuscript.

All authors declare that they have no conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in this current opinion article.

References

  1. 1.
    Edwards R, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000; 356: 1255–9PubMedCrossRefGoogle Scholar
  2. 2.
    Leendertse AJ, Egberts ACG, Stoker LJ, et al. Frequency of and risk factors for preventable medication-related hospital admissions in the Netherlands. Arch Intern Med 2008; 168(17): 1890–6PubMedCrossRefGoogle Scholar
  3. 3.
    Mannesse CK, Derkx FH, de Ridder MA, et al. Adverse drug reactions in elderly patients as contributing factor for hospital admission: cross sectional study. BMJ 1997; 315: 1057–8PubMedCrossRefGoogle Scholar
  4. 4.
    van der Linden CMJ, Kerskes CH, Bijl AMH, et al. Represcription after adverse drug reaction in the elderly: a descriptive study. Arch Intern Med 2006; 166: 1666–7PubMedCrossRefGoogle Scholar
  5. 5.
    Aronson JK, Ferner RE. Joining the DoTS: new approach to classifying adverse drug reactions. BMJ 2003; 327: 1222–5PubMedCrossRefGoogle Scholar
  6. 6.
    Naranjo CAA. Method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30(2): 239–45PubMedCrossRefGoogle Scholar
  7. 7.
    Kramer MS, Leventhal JM, Hutchinson TA, et al. An algorithm for the operational assessment of adverse drug reactions: I. Background, description and instructions for use. JAMA 1979; 242: 623–32PubMedCrossRefGoogle Scholar
  8. 8.
    European Medicines Agency. Clinical safety data management: definitions and standards for expedited reporting (June 1995) [online]. Available from URL: http://www.emea.europa.eu/pdfs/human/ich/037795en.pdf. [Accessed 2009 Jun 10]

Copyright information

© Adis Data Information BV 2010

Authors and Affiliations

  • Carolien M. J. van der Linden
    • 1
  • Paul A. F. Jansen
    • 2
  • Rob J. van Marum
    • 2
    • 3
  • René J. E. Grouls
    • 1
  • Erik H. M. Korsten
    • 1
    • 4
  • Antoine C. G. Egberts
    • 2
    • 5
  1. 1.Catharina HospitalEindhoventhe Netherlands
  2. 2.University Medical Centre UtrechtUtrechtthe Netherlands
  3. 3.Jeroen Bosch Hospital’s-Hertogenboschthe Netherlands
  4. 4.Eindhoven University of TechnologyEindhoventhe Netherlands
  5. 5.Utrecht Institute for Pharmaceutical SciencesUtrechtthe Netherlands

Personalised recommendations